Furthermore, the higher frequencies of amplification in ERBB2 reported in some studies of clear cell and mucinous carcinomas of the ovary suggest that anti-HER2 directed therapy may be more beneficial in these subgroups (Table 1 and Table 2) [22,37,122]. This evidence concerns the gene ERBB2 and ovarian mucinous adenocarcinoma.